anastrozole has been researched along with Metastase in 52 studies
Excerpt | Relevance | Reference |
---|---|---|
"We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy." | 9.30 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019) |
"We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)." | 9.27 | Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018) |
"After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 9.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
"The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard." | 9.16 | Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012) |
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 9.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
"To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane." | 9.10 | Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003) |
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment." | 9.10 | Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002) |
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment." | 9.10 | Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002) |
" Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 8.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
"In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 8.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
"To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
"To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer." | 7.74 | [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008) |
"We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 7.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
"At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event." | 6.82 | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016) |
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 6.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen." | 6.42 | Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004) |
"Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings." | 5.33 | Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006) |
"We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy." | 5.30 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019) |
"We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)." | 5.27 | Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018) |
"After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 5.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
"The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard." | 5.16 | Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012) |
"Bevacizumab combined with either anastrozole or fulvestrant was feasible and active in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer." | 5.15 | Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. ( Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA, 2011) |
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 5.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
"To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin." | 5.14 | Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. ( Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V, 2010) |
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment." | 5.10 | Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002) |
"To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane." | 5.10 | Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003) |
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment." | 5.10 | Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002) |
"Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
" For more than 20 years, standard first-line treatment for postmenopausal women with metastatic breast cancer has been the antiestrogen tamoxifen, a selective estrogen receptor modulator (SERM) with differential effects on breast, endometrial, bone, and vascular tissues." | 4.82 | Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. ( Brodie, AH; Mouridsen, HT, 2003) |
" Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 4.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
" In women with hormone-sensitive breast cancer, three of these agents, letrozole, anastrozole, and exemestane, provide an important alternative endocrine therapy to the antiestrogen tamoxifen, which blocks estrogen activation of the estrogen receptor." | 4.82 | Aromatase inhibitors in advanced breast cancer. ( Mouridsen, HT, 2004) |
"During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion." | 4.81 | [Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002) |
"Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)." | 4.80 | The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999) |
"In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 4.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
"A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole, anastrozole or exemestane) were analyzed retrospectively." | 3.81 | [Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases]. ( Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M, 2015) |
"To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
"To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer." | 3.74 | [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008) |
"We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 3.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
"At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event." | 2.82 | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016) |
"Type I endometrial cancer is a common tumor of the female genital tract." | 2.53 | Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016) |
"The natural history of HR+ breast cancer tends to be different from hormone receptor-negative disease in terms of time to recurrence, site of recurrence and overall aggressiveness of the disease." | 2.50 | Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. ( Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ, 2014) |
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen." | 2.42 | Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004) |
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 2.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
"The primary end point was distant metastasis (DM)." | 1.39 | The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. ( Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE, 2013) |
"This case is an example of breast cancer presenting with paraneoplastic manifestations." | 1.35 | A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report. ( Cheung, KL; Haynes, AP; Wood, JP, 2008) |
"The San Antonio Breast Cancer Symposium is now considered the most important international breast cancer meeting worldwide." | 1.33 | Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. ( Ponzone, R; Sismondi, P, 2005) |
"Metastatic breast cancer (MBC) is incurable in most cases." | 1.33 | Does survival increase in metastatic breast cancer with recently available anticancer drugs? ( Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F, 2006) |
"Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings." | 1.33 | Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (5.77) | 18.2507 |
2000's | 24 (46.15) | 29.6817 |
2010's | 23 (44.23) | 24.3611 |
2020's | 2 (3.85) | 2.80 |
Authors | Studies |
---|---|
Edmondson, RJ | 1 |
O'Connell, RL | 1 |
Banerjee, S | 1 |
Mileshkin, L | 1 |
Sykes, P | 1 |
Beale, P | 1 |
Fisher, A | 1 |
Bonaventura, A | 1 |
Millan, D | 1 |
Nottley, S | 1 |
Benson, C | 1 |
Hamilton, A | 2 |
Sjoquist, K | 1 |
Alexander, L | 1 |
Kelly, C | 1 |
Carty, K | 1 |
Divers, L | 1 |
Bradshaw, N | 1 |
Friedlander, M | 1 |
Maguire, M | 1 |
Drumm, C | 1 |
Woods, G | 1 |
Mullally, W | 1 |
Redmond, M | 1 |
Grogan, L | 1 |
O'Kane, M | 1 |
Wagner, LI | 1 |
Zhao, F | 1 |
Goss, PE | 1 |
Chapman, JW | 1 |
Shepherd, LE | 1 |
Whelan, TJ | 1 |
Mattar, BI | 1 |
Bufill, JA | 1 |
Schultz, WC | 1 |
LaFrancis, IE | 1 |
Nagargoje, GG | 1 |
Vemuri, R | 1 |
Nikcevich, DA | 1 |
Sledge, GW | 2 |
Cella, D | 1 |
Kim, JY | 1 |
Im, SA | 1 |
Jung, KH | 1 |
Ro, J | 1 |
Sohn, J | 1 |
Kim, JH | 1 |
Park, YH | 1 |
Kim, TY | 1 |
Kim, SB | 1 |
Lee, KS | 1 |
Kim, GM | 1 |
Kim, SH | 1 |
Kim, S | 1 |
Ahn, JS | 1 |
Lee, KH | 1 |
Ahn, JH | 1 |
Park, IH | 1 |
Im, YH | 2 |
Mehta, RS | 2 |
Barlow, WE | 2 |
Albain, KS | 2 |
Vandenberg, TA | 2 |
Dakhil, SR | 2 |
Tirumali, NR | 2 |
Lew, DL | 2 |
Hayes, DF | 2 |
Gralow, JR | 2 |
Linden, HH | 1 |
Livingston, RB | 2 |
Hortobagyi, GN | 3 |
Burki, TK | 1 |
Johnston, SR | 1 |
Kilburn, LS | 1 |
Ellis, P | 1 |
Dodwell, D | 1 |
Cameron, D | 1 |
Hayward, L | 1 |
Braybrooke, JP | 1 |
Brunt, AM | 1 |
Cheung, KL | 2 |
Jyothirmayi, R | 1 |
Robinson, A | 1 |
Wardley, AM | 1 |
Wheatley, D | 1 |
Howell, A | 3 |
Coombes, G | 1 |
Sergenson, N | 1 |
Sin, HJ | 1 |
Folkerd, E | 1 |
Dowsett, M | 2 |
Bliss, JM | 1 |
Dubsky, P | 1 |
Brase, JC | 1 |
Jakesz, R | 1 |
Rudas, M | 1 |
Singer, CF | 1 |
Greil, R | 1 |
Dietze, O | 1 |
Luisser, I | 1 |
Klug, E | 1 |
Sedivy, R | 1 |
Bachner, M | 1 |
Mayr, D | 1 |
Schmidt, M | 1 |
Gehrmann, MC | 1 |
Petry, C | 1 |
Weber, KE | 1 |
Fisch, K | 1 |
Kronenwett, R | 1 |
Gnant, M | 1 |
Filipits, M | 1 |
Campos-Gómez, S | 1 |
Flores-Arredondo, JH | 1 |
Dorantes-Heredia, R | 1 |
Chapa-Ibargüengoitia, M | 1 |
de la Peña-Lopez, R | 1 |
Dalmau, E | 1 |
Armengol-Alonso, A | 1 |
Muñoz, M | 1 |
Seguí-Palmer, MÁ | 1 |
Bogliolo, S | 1 |
Gardella, B | 1 |
Dominoni, M | 1 |
Musacchi, V | 1 |
Cassani, C | 1 |
Zanellini, F | 1 |
De Silvestri, A | 1 |
Gaggero, CR | 1 |
Babilonti, L | 1 |
Spinillo, A | 1 |
Zhang, M | 1 |
Yan, M | 1 |
Lü, H | 1 |
Niu, L | 1 |
Zeng, H | 1 |
Cui, S | 1 |
Beauchemin, C | 1 |
Letarte, N | 1 |
Mathurin, K | 1 |
Yelle, L | 1 |
Lachaine, J | 1 |
Sansone, P | 1 |
Ceccarelli, C | 1 |
Berishaj, M | 1 |
Chang, Q | 1 |
Rajasekhar, VK | 1 |
Perna, F | 1 |
Bowman, RL | 1 |
Vidone, M | 1 |
Daly, L | 1 |
Nnoli, J | 1 |
Santini, D | 1 |
Taffurelli, M | 1 |
Shih, NN | 1 |
Feldman, M | 1 |
Mao, JJ | 1 |
Colameco, C | 1 |
Chen, J | 1 |
DeMichele, A | 1 |
Fabbri, N | 1 |
Healey, JH | 1 |
Cricca, M | 1 |
Gasparre, G | 1 |
Lyden, D | 1 |
Bonafé, M | 1 |
Bromberg, J | 1 |
Johnston, S | 1 |
Basik, M | 1 |
Hegg, R | 1 |
Lausoontornsiri, W | 1 |
Grzeda, L | 1 |
Clemons, M | 1 |
Dreosti, L | 1 |
Mann, H | 1 |
Stuart, M | 1 |
Cristofanilli, M | 2 |
Ellis, MJ | 1 |
Suman, VJ | 1 |
Hoog, J | 1 |
Goncalves, R | 1 |
Sanati, S | 1 |
Creighton, CJ | 1 |
DeSchryver, K | 1 |
Crouch, E | 1 |
Brink, A | 1 |
Watson, M | 1 |
Luo, J | 1 |
Tao, Y | 1 |
Barnes, M | 1 |
Budd, GT | 1 |
Winer, E | 1 |
Silverman, P | 1 |
Esserman, L | 1 |
Carey, L | 1 |
Ma, CX | 1 |
Unzeitig, G | 1 |
Pluard, T | 1 |
Whitworth, P | 1 |
Babiera, G | 1 |
Guenther, JM | 1 |
Dayao, Z | 1 |
Ota, D | 1 |
Leitch, M | 1 |
Olson, JA | 1 |
Allred, DC | 1 |
Hunt, K | 1 |
Wood, JP | 1 |
Haynes, AP | 1 |
Barker, LC | 1 |
Brand, IR | 1 |
Crawford, SM | 1 |
Kaufman, B | 1 |
Mackey, JR | 1 |
Clemens, MR | 1 |
Bapsy, PP | 1 |
Vaid, A | 1 |
Wardley, A | 1 |
Tjulandin, S | 1 |
Jahn, M | 1 |
Lehle, M | 1 |
Feyereislova, A | 1 |
Révil, C | 1 |
Jones, A | 1 |
Doyen, J | 1 |
Italiano, A | 1 |
Largillier, R | 1 |
Ferrero, JM | 1 |
Fontana, X | 1 |
Thyss, A | 1 |
Valero, V | 2 |
Mangalik, A | 1 |
Royce, M | 1 |
Rabinowitz, I | 1 |
Arena, FP | 1 |
Kroener, JF | 1 |
Curcio, E | 1 |
Watkins, C | 1 |
Bacus, S | 1 |
Cora, EM | 1 |
Anderson, E | 1 |
Magill, PJ | 1 |
Carlson, RW | 3 |
Theriault, R | 1 |
Schurman, CM | 1 |
Rivera, E | 1 |
Chung, CT | 1 |
Phan, SC | 1 |
Arun, B | 1 |
Dice, K | 1 |
Chiv, VY | 1 |
Green, M | 1 |
Harris, CA | 1 |
Ward, RL | 1 |
Dobbins, TA | 1 |
Drew, AK | 1 |
Pearson, S | 1 |
Doughty, JC | 1 |
Yardley, DA | 1 |
Burris, HA | 1 |
Clark, BL | 1 |
Shipley, D | 1 |
Rubin, M | 1 |
Barton, J | 1 |
Arrowsmith, E | 1 |
Hainsworth, JD | 1 |
Cruz Jurado, J | 1 |
Richart Aznar, P | 1 |
García Mata, J | 1 |
Fernández Martínez, R | 1 |
Peláez Fernández, I | 1 |
Sampedro Gimeno, T | 1 |
Galve Calvo, E | 1 |
Murillo Jaso, L | 1 |
Polo Marqués, E | 1 |
García Palomo, A | 1 |
O'Neill, A | 1 |
Vidaurre, T | 1 |
Gomez, HL | 1 |
Badve, SS | 1 |
Osborne, CK | 1 |
Pippen, J | 1 |
Jones, SE | 1 |
Parker, LM | 1 |
Ellis, M | 1 |
Come, S | 1 |
Gertler, SZ | 1 |
May, JT | 1 |
Burton, G | 1 |
Dimery, I | 1 |
Webster, A | 2 |
Morris, C | 2 |
Elledge, R | 1 |
Buzdar, A | 1 |
Robertson, JF | 2 |
Quaresma Albano, J | 1 |
Aschermannova, A | 1 |
Mauriac, L | 1 |
Kleeberg, UR | 1 |
Vergote, I | 2 |
Erikstein, B | 1 |
Miyoshi, Y | 1 |
Taguchi, T | 1 |
Tamaki, Y | 1 |
Noguchi, S | 1 |
Brodie, AH | 1 |
Mouridsen, HT | 2 |
Rose, C | 1 |
Carlini, P | 1 |
Ferretti, G | 1 |
Di Cosimo, S | 1 |
Colella, E | 1 |
Tonachella, R | 1 |
Romiti, A | 1 |
Tomao, S | 1 |
Frassoldati, A | 1 |
Papaldo, P | 1 |
Fabi, A | 1 |
Ruggeri, EM | 1 |
Cognetti, F | 1 |
Mouridsen, H | 1 |
Gershanovich, M | 1 |
Henderson, IC | 1 |
McKeage, K | 1 |
Curran, MP | 1 |
Plosker, GL | 1 |
Okubo, S | 1 |
Sonoo, H | 2 |
Hirono, M | 1 |
Nomura, T | 2 |
Udagawa, K | 1 |
Ikeda, M | 2 |
Nakashima, K | 2 |
Tanaka, K | 2 |
Kurebayashi, J | 2 |
Ponzone, R | 1 |
Sismondi, P | 1 |
Abrial, C | 1 |
Leheurteur, M | 1 |
Cabrespine, A | 1 |
Mouret-Reynier, MA | 1 |
Durando, X | 1 |
Ferriere, JP | 1 |
Kwiatkowski, F | 1 |
Penault-Llorca, F | 1 |
Cure, H | 1 |
Chollet, P | 1 |
Langenegger, T | 1 |
Wahl, P | 1 |
Schiesser, D | 1 |
Thürlimann, B | 1 |
El-Saghir, NS | 1 |
El-Hajj, II | 1 |
Makarem, JA | 1 |
Otrock, ZK | 1 |
Herold, CI | 1 |
Blackwell, KL | 1 |
Miyake, A | 1 |
Yamamoto, Y | 1 |
Shiiki, S | 1 |
Buzdar, AU | 1 |
Plourde, PV | 1 |
Piccart, M | 1 |
Messori, A | 1 |
Cattel, F | 1 |
Trippoli, S | 1 |
Vaiani, M | 1 |
Winer, EP | 1 |
Burstein, HJ | 1 |
Alba, E | 1 |
Ragonesi, G | 1 |
Colla, F | 1 |
Mazzoleni, A | 1 |
Farina, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman[NCT01266213] | Phase 2 | 147 participants (Anticipated) | Interventional | 2010-12-31 | Active, not recruiting | ||
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer[NCT00075764] | Phase 3 | 695 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-[NCT00253422] | Phase 3 | 750 participants (Anticipated) | Interventional | 2004-03-31 | Active, not recruiting | ||
A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-st[NCT00944918] | Phase 3 | 25 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799] | 1,191 participants (Actual) | Observational [Patient Registry] | 2018-07-17 | Active, not recruiting | |||
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Th[NCT01151215] | Phase 2 | 482 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Futility) | ||
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer[NCT00265759] | Phase 3 | 622 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study[NCT01953588] | Phase 3 | 1,473 participants (Actual) | Interventional | 2013-12-13 | Active, not recruiting | ||
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761] | Phase 1 | 6 participants (Actual) | Interventional | 2021-09-10 | Active, not recruiting | ||
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
Phase II Study of Pyrotinib in Combination With Fulvestrant in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive,Hormone Receptor(HR)-Positive Metastatic Breast Cancer[NCT04034589] | Phase 2 | 46 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positi[NCT03644186] | Phase 2 | 144 participants (Actual) | Interventional | 2019-04-16 | Completed | ||
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women[NCT00186121] | Phase 2 | 35 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)[NCT00405938] | Phase 2 | 79 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic [NCT00057941] | Phase 2 | 148 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice[NCT01425294] | 231 participants (Actual) | Observational | 2011-08-01 | Terminated (stopped due to The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The use mothod of 250mg per month in clinical practice is off-label.) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable, Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Clinical Benefit = CR + PR + Stable >= 24 weeks (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
Intervention | percentage of participants (Number) |
---|---|
Arm I Anastrozole | 70 |
Arm II Anastrozole and Fulvestrant | 73 |
From date of randomization to date of death due to any cause. Patients last known to be alive are censored at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
Intervention | months (Median) |
---|---|
Arm I Anastrozole | 41.3 |
Arm II Anastrozole and Fulvestrant | 47.7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
Intervention | months (Median) |
---|---|
Arm I Anastrozole | 13.5 |
Arm II Anastrozole and Fulvestrant | 15.0 |
Adverse Events (AEs) are reported by CTCAE version 3.0 terminology. For each patient, worst grade of each event type is reported. Grade3 (Severe), Grade4 (Life-threatening), Grade 5 (Fatal) (NCT00075764)
Timeframe: Patients were assessed for adverse events after each cycle (1 cycle = 28 days) while on treatment.
Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALT, SGPT (serum glutamic pyruvic transaminase) | AST, SGOT | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Bilirubin (hyperbilirubinemia) | CNS cerebrovascular ischemia | Calcium, serum-high (hypercalcemia) | Cataract | Confusion | Constipation | Dehydration | Diarrhea | Dizziness | Dyspnea (shortness of breath) | Edema: limb | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fracture | Glucose, serum-high (hyperglycemia) | Hemoglobin | Hemolysis | Hot flashes/flushes | Hypertension | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Infection with unknown ANC - Urinary tract NOS | Insomnia | Joint-effusion | Leukocytes (total WBC) | Lymphopenia | Memory impairment | Mood alteration - agitation | Mood alteration - anxiety | Mood alteration - depression | Mucositis/stomatitis (functional/symp) - Pharynx | Muscle weakness, not d/t neuropathy - body/general | Nausea | Neurology-Other (Specify) | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Back | Pain - Bone | Pain - Breast | Pain - Buttock | Pain - Chest wall | Pain - Chest/thorax NOS | Pain - Extremity-limb | Pain - Head/headache | Pain - Joint | Pain - Muscle | Pain - Neck | Pain - Pelvis | Pain-Other (Specify) | Platelets | Rash/desquamation | Sodium, serum-low (hyponatremia) | Speech impairment (e.g., dysphasia or aphasia) | Sudden death | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Tinnitus | Tumor flare | Urticaria (hives, welts, wheals) | Vomiting | Weight gain | |
Arm I Anastrozole | 1 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 7 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 1 | 5 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 5 | 3 | 0 | 0 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 3 | 6 | 0 | 0 | 0 | 3 | 0 |
Arm II Anastrozole and Fulvestrant | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 9 | 0 | 2 | 2 | 3 | 1 | 7 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 3 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 7 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 7 | 0 | 1 | 3 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 7 | 1 | 2 | 1 | 2 | 1 |
Time from the date of randomization to the date of death (by any cause) (NCT01151215)
Timeframe: Following progression, patients were contacted at 12 weekly intervals until data cut-off at 31 August 2012 to determine survival status
Intervention | Months (Median) |
---|---|
AZD8931 40mg + Anastrozole 1mg | 6.9 |
AZD8931 20mg + Anastrozole 1mg | 8.3 |
Placebo + Anastrozole 1mg | 7.9 |
Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as >=20% increase in the sum of longest diameters of target lesions and an absolute increase of >=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions. (NCT01151215)
Timeframe: Tumour assessment by RECIST 1.1 every 12 weeks until data cut-off at 31 August 2012
Intervention | Months (Median) |
---|---|
AZD8931 40mg + Anastrozole 1mg | 13.8 |
AZD8931 20mg + Anastrozole 1mg | 10.9 |
Placebo + Anastrozole 1mg | 14.0 |
The primary aim is to assess the anti-tumor effect in terms of pathologic CR rates of neo-adjuvant chemotherapy in patients with T2-T4c, any N, M0 breast cancer (by clinical staging) who are endocrine therapy resistant (that is, their Ki-67 level is >10 after 2-4 week of neo-adjuvant endocrine therapy alone). The pCR rate (percentage) for neo-adjuvant chemotherapy is defined as 100 times the number of eligible patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary or sentinel lymph nodes divided by the total number of eligible patients who received neo-adjuvant chemotherapy. (NCT00265759)
Timeframe: Up to 18 weeks
Intervention | percentage of patients (Number) |
---|---|
Cohort B Arm II: Week 2 Ki67 > 10% | 5.7 |
The clinical response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose disease meets the WHO criteria for complete or partial response prior to surgery divided by the total number of eligible patients randomized to that treatment. For each treatment arm, a 95% binomial confidence interval will be constructed for the true clinical response rate. Complete Response (CR): The disappearance of all known disease based on a comparison between the measurements at baseline and the Week 16 visit. Partial Response (PR): A 50% or greater decrease in the product of the bi-dimensional measurements of the lesion (total tumor size) based on a comparison between the measurements at baseline and the Week 16 visit. In addition there can be no appearance of new lesions or progression of any lesion. (NCT00265759)
Timeframe: Up to 18 weeks
Intervention | percentage of patients (Number) |
---|---|
Cohort A Arm I: Exemestane | 62.9 |
Cohort A Arm II: Letrozole | 74.8 |
Cohort A Arm III: Anastrozole | 69.1 |
The rate (percentage) of improved surgical outcome for patients considered marginal for breast conservation surgery prior to therapy for Cohort A is reported below for each treatment arm. Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
Intervention | percentage of improved surgical outcome (Number) |
---|---|
Cohort A Arm I: Exemestane | 85.2 |
Cohort A Arm II: Letrozole | 77.4 |
Cohort A Arm III: Anastrozole | 86.4 |
Rate (percentage) of Improved surgical outcome for patients designated as candidates for mastectomy prior to therapy (Cohort A). Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
Intervention | percentage of patients (Number) |
---|---|
Cohort A Arm I: Exemestane | 48.1 |
Cohort A Arm II: Letrozole | 42.1 |
Cohort A Arm III: Anastrozole | 60.0 |
For those patients who undergo a sentinel lymph node dissection or an axillary lymph node dissection (at least 6 nodes examined with Hematoxylin & Eosin Staining), the LNI rate (percentage) is defined as 100 times the proportion of eligible patients randomized to that treatment with at least one positive node. For each neo-adjuvant endocrine treatment, a 95% binomial confidence interval will be constructed for its true LNI rate. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
Intervention | percentage of patients (Number) |
---|---|
Cohort A Arm I: Exemestane | 41.1 |
Cohort A Arm II: Letrozole | 48.2 |
Cohort A Arm III: Anastrozole | 44.1 |
The pathologic complete response is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes. The pathologic complete response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose surgical specimen is such that there is no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes divided by the total number of eligible patients randomized to that treatment. For each neo-adjuvant endocrine treatment pair, a 95% binomial confidence interval will be constructed for the true difference in the pCR between these 2 treatments. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
Intervention | percentage of patients (Number) |
---|---|
Cohort A Arm I: Exemestane | 1.7 |
Cohort A Arm II: Letrozole | 0.0 |
Cohort A Arm III: Anastrozole | 0.0 |
Incidence of the most common grade 3+ toxicities reported to be probably, possibly, or definitely related to treatment as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Cohort A) At each treatment evaluation, the type, severity, and attribution of each adverse event reported will be assessed using the NCI-CTCAE definitions. For each treatment, the percentage of patients who developed a severe (grade 3+) toxicity considered possibly, probably or definitively related to treatment will be determined. (NCT00265759)
Timeframe: Up to 30 days after drug therapy
Intervention | percentage of patients (Number) | ||
---|---|---|---|
Fatigue | Hot flashes/flushes | Joint pain | |
Cohort A Arm I: Exemestane | 2 | 2 | 2 |
Cohort A Arm II: Letrozole | 2 | 4 | 3 |
Cohort A Arm III: Anastrozole | 3 | 2 | 2 |
"The overall clinical benefit rate of goserelin followed by anastrozole was evaluated, as determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rate + Stable Disease (SD) rate.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
Anastrozole + Goserelin | 71.9 |
"ORR was determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rates.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 3 months
Intervention | percentage of participants (Number) |
---|---|
Anastrozole + Goserelin | 37.5 |
Overall survival (OS) was assessed as the median observed in the participants receiving goserelin followed by anastrozole. (NCT00186121)
Timeframe: up to 63 months
Intervention | months (Median) |
---|---|
Anastrozole + Goserelin | NA |
The toxicity of the treatment regimen of goserelin followed by anastrozole is estimated by the rate of Serious Adverse Events (SAEs) that occurred during the course of the study. (NCT00186121)
Timeframe: 6 months
Intervention | Serious Adverse Events (SAEs) (Number) |
---|---|
Anastrozole + Goserelin | 0 |
"Time-to-progression (TTP) was assessed as the median observed in the participant group.~Progression of disease was considered, per protocol, to be ≤ 25% increase in the area of any malignant lesion greater than 2 square cm, or ≤ 25% increase in the sum of the products of the longest perpendicular diameters of individual lesions in a given organ, when compared to baseline values or after therapeutic response." (NCT00186121)
Timeframe: up to 63 months
Intervention | months (Median) |
---|---|
Anastrozole + Goserelin | 8.3 |
Plasma estradiol determinations were performed at baseline, 1 month, 3 months, and 6 months using the Coat-A-Count Estradiol competitive binding assay system, which has a calibrated range for estradiol of 20 to 3,600 pg/mL with an analytical sensitivity of 10 pg/mL. (NCT00186121)
Timeframe: 6 months
Intervention | pg/mL estradiol (Mean) | |||
---|---|---|---|---|
Mean at Baseline | Mean at 1 month treatment | Mean at 3 months treatment | Mean at 6 months treatment | |
Anastrozole + Goserelin | 74.7 | 20.8 | 18.7 | 14.8 |
"The numbers of participants with metastatic breast cancer experiencing Complete Response (CR); Partial Response (PR); or Stable Disease (SD) after treatment with goserelin followed by anastrozole are reported.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | |
Anastrozole + Goserelin | 1 | 11 | 11 |
The Percentage of Patients Who Experience an Objective Benefit From Treatment (CR+PR). The response categories were assigned using RECIST criteria. Complete Response (CR) = Disappearance of all target lesions ; Partial Response (PR) = >=30% decrease in the sum of the longest diameter of target lesions. (NCT00405938)
Timeframe: 18 months
Intervention | Participants (Count of Participants) |
---|---|
Bevacizumab/Anastrozole | 18 |
Bevacizumab/Fulvestrant | 11 |
Progression Free Survival (PFS) is defined as the interval, in months, from the date of first treatment to the date of disease progression or death, whichever occurred first. (NCT00405938)
Timeframe: 18 months
Intervention | months (Median) |
---|---|
Bevacizumab/Anastrozole | 21 |
Bevacizumab/Fulvestrant | 9 |
Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease <30% or increase <20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included. (NCT00057941)
Timeframe: assessed every 3 cycles while on treatment, assessed every 3 months when follow up <2 years, every 6 months between 2-3 years,no specific requirements after 3 years
Intervention | percentage of participants (Number) |
---|---|
Anastrozole and ZD1839 | 44 |
Fulvestrant and ZD1839 | 41 |
18 reviews available for anastrozole and Metastase
Article | Year |
---|---|
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistanc | 2014 |
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria | 2016 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemoth | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2004 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2004 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
15 trials available for anastrozole and Metastase
Article | Year |
---|---|
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Carcinosarcoma; Female; Humans; L | 2021 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2019 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem | 2010 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2003 |
19 other studies available for anastrozole and Metastase
Article | Year |
---|---|
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast | 2020 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality The | 2018 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2019 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease | 2014 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin | 2008 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aroma | 2010 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol | 2004 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2006 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2008 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Met | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Fem | 1996 |